前立腺特異的膜抗原（PSMA）陽性の転移性去勢抵抗性前立腺癌（mCRPC）に対し、PSMAを標的とする[177Lu]Lu-PSMA-617（177Lu-PSMA-617）の有効性を示したPSMAfore試験の探索的解析で、ベースラインおよび治療中の循環腫瘍DNA（ctDNA）は予後と効果に関連することが ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
PSMA陽性転移性ホルモン感受性前立腺癌（mHSPC）に対して、標準治療であるアンドロゲン除去療法（ADT）とアンドロゲン受容体経路阻害薬（ARPI）に、[177Lu]Lu-PSMA-617（177Lu-PSMA-617）を併用することで画像学的無増悪生存期間（rPFS）が有意に改善したことが ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by ...
LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...
A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph's Health Care London (Lawson), and University Health Network (UHN) has ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する